Jason Drew Smith - 07 Sep 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Sep 2026, 14:35:46 UTC
Prior SEC filing
11 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Jason Drew Smith filed Form 4 for UroGen Pharma Ltd. (URGN) on 09 Sep 2026.

Key facts

  • This page summarizes Jason Drew Smith's Form 4 filing for UroGen Pharma Ltd. (URGN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 09 Sep 2026, 14:35.

Change

  • Previous filing in this sequence was filed on 11 Feb 2026.
  • Current net transaction value: -$64,618.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821479 Primary reporting owner

Smith Jason Drew

Relationship
General Counsel
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Signature date
09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

URGN transaction

Ordinary Shares

Options Exercise

Transaction value
Shares
+3,334
Change %
+6.5%
Price
Shares after
54,660
Date
07 Sep 2026
Ownership
Direct
Footnotes
F1
URGN transaction

Ordinary Shares

Sale

Transaction value
$64,618
Shares
-1,519
Change %
-2.8%
Price
$42.54
Shares after
53,141
Date
08 Sep 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-3,334
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 Sep 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
3,334
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

Footnote F2

Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

Footnote F3

The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .